IntroductionChronic urticaria (CU) may seem as a non‐life‐threatening disease, but in reality, it is severe and often debilitating especially due to the itch. It may lead to the loss of both the social life and work of the patients. Chronic spontaneous urticaria (CSU) is characterized by the spontaneous appearance of widespread edematous, pruritic wheals surrounded by a red flare that lasts ≥6 weeks and can recur. CSU is a challenge in regard to treatment. Current international guidelines propose that second‐generation non‐sedating antihistamines constitute the first line of treatment for urticaria, whether acute or chronic. The European Academy of Allergology and Clinical Immunology/Global Allergy and Asthma European Network/European Dermatology Forum/World Allergy Organization (EAACI/GA2LEN/EDF/WAO) guidelines state that before considering an alternative treatment, a trial of second‐generation antihistamines at doses up to four times indicated is warranted for patients who do not respond to standard doses when the potential benefits outweigh any risks. In addition, increased antihistamine doses improve patient quality of life without increasing somnolence. Once this disease is completely controlled, however, the optimal method for reducing the dose of antihistamine has not been determined.Desloratadine is a non‐sedating, second‐generation H1‐antihistamine. Overall, the quality of evidence is high for desloratadine being safe
International Journal of Dermatology – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera